S11

S11 is a novel small molecule histone deacetylase (HDAC) inhibitor that also exhibits P-glycoprotein (P-gp) inhibitory activity. It has been specifically investigated for its ability to reverse cisplatin resistance in non-small cell lung cancer (NSCLC). S11 works by targeting the HDAC/OAZ1 axis; its inhibition of HDAC leads to an accumulation of acetylated histone H4 (Ac-H4) in the promoter region of the OAZ1 gene, thereby upregulating OAZ1 (ornithine decarboxylase antizyme 1) expression. Additionally, S11 increases the expression of p21 and suppresses tumor cell growth, colony formation, and migration. In preclinical models, S11 demonstrates synergistic efficacy when combined with cisplatin, effectively sensitizing resistant cancer cells to chemotherapy.